CN111419835A - 苯磺酰胺化合物作为mPGES-2抑制剂及药物的用途 - Google Patents
苯磺酰胺化合物作为mPGES-2抑制剂及药物的用途 Download PDFInfo
- Publication number
- CN111419835A CN111419835A CN202010422229.XA CN202010422229A CN111419835A CN 111419835 A CN111419835 A CN 111419835A CN 202010422229 A CN202010422229 A CN 202010422229A CN 111419835 A CN111419835 A CN 111419835A
- Authority
- CN
- China
- Prior art keywords
- substituted
- mpges
- alkyl
- phenyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010422229.XA CN111419835B (zh) | 2020-05-18 | 2020-05-18 | 苯磺酰胺化合物在制备治疗糖尿病的药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010422229.XA CN111419835B (zh) | 2020-05-18 | 2020-05-18 | 苯磺酰胺化合物在制备治疗糖尿病的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111419835A true CN111419835A (zh) | 2020-07-17 |
CN111419835B CN111419835B (zh) | 2021-09-21 |
Family
ID=71553075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010422229.XA Active CN111419835B (zh) | 2020-05-18 | 2020-05-18 | 苯磺酰胺化合物在制备治疗糖尿病的药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111419835B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113413381A (zh) * | 2021-08-10 | 2021-09-21 | 徐州医科大学 | 苯磺酰胺化合物在制备治疗急性肾损伤的药物中的应用 |
CN113413380A (zh) * | 2021-08-10 | 2021-09-21 | 徐州医科大学 | mPGES-2抑制剂在制备治疗和/或预防非酒精性脂肪肝病的药物中的用途 |
CN113521288A (zh) * | 2021-08-10 | 2021-10-22 | 徐州医科大学 | mPGES-2作为治疗和/或预防脂肪性肝病的药物靶点的应用 |
CN113549687A (zh) * | 2021-08-10 | 2021-10-26 | 徐州医科大学 | mPGES-2作为预防和/或治疗肾脏疾病的药物靶点的应用 |
CN114107272A (zh) * | 2021-12-15 | 2022-03-01 | 徐州医科大学 | mPGES-2作为预防和/或治疗衰老疾病的药物靶点的应用 |
CN114129577A (zh) * | 2021-12-15 | 2022-03-04 | 徐州医科大学 | 苯磺酰胺化合物在制备预防和/或治疗衰老疾病的药物中的用途 |
CN114748487A (zh) * | 2022-03-22 | 2022-07-15 | 徐州医科大学 | 苯磺酰胺化合物在制备调节麻醉效应的药物中的用途 |
CN115590862A (zh) * | 2022-11-08 | 2023-01-13 | 徐州医科大学(Cn) | 苯磺酰胺化合物在制备治疗和/或预防常染色体显性遗传多囊肾病的药物中的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101817767A (zh) * | 2009-02-26 | 2010-09-01 | 中国科学院上海药物研究所 | 取代磺酰胺类化合物及其制备方法、药物组合物和应用 |
CN102970867A (zh) * | 2010-03-18 | 2013-03-13 | 拜耳知识产权有限责任公司 | 作为活性剂对抗非生物植物应激的芳基和杂芳基磺酰胺 |
-
2020
- 2020-05-18 CN CN202010422229.XA patent/CN111419835B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101817767A (zh) * | 2009-02-26 | 2010-09-01 | 中国科学院上海药物研究所 | 取代磺酰胺类化合物及其制备方法、药物组合物和应用 |
CN102970867A (zh) * | 2010-03-18 | 2013-03-13 | 拜耳知识产权有限责任公司 | 作为活性剂对抗非生物植物应激的芳基和杂芳基磺酰胺 |
Non-Patent Citations (2)
Title |
---|
HUI HU等: "A novel class of antagonists for the FFAs receptor GPR40", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 * |
KRISTIN M. BOMPIANI等: "High-Throughput Screening Uncovers Novel Botulinum Neurotoxin Inhibitor Chemotypes", 《ACS COMBINATORIAL SCIENCE》 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113413381A (zh) * | 2021-08-10 | 2021-09-21 | 徐州医科大学 | 苯磺酰胺化合物在制备治疗急性肾损伤的药物中的应用 |
CN113413380A (zh) * | 2021-08-10 | 2021-09-21 | 徐州医科大学 | mPGES-2抑制剂在制备治疗和/或预防非酒精性脂肪肝病的药物中的用途 |
CN113521288A (zh) * | 2021-08-10 | 2021-10-22 | 徐州医科大学 | mPGES-2作为治疗和/或预防脂肪性肝病的药物靶点的应用 |
CN113549687A (zh) * | 2021-08-10 | 2021-10-26 | 徐州医科大学 | mPGES-2作为预防和/或治疗肾脏疾病的药物靶点的应用 |
CN113413381B (zh) * | 2021-08-10 | 2021-12-17 | 徐州医科大学 | 苯磺酰胺化合物在制备治疗急性肾损伤的药物中的应用 |
CN113413380B (zh) * | 2021-08-10 | 2022-03-08 | 徐州医科大学 | mPGES-2抑制剂在制备治疗和/或预防非酒精性脂肪肝病的药物中的用途 |
CN114107272A (zh) * | 2021-12-15 | 2022-03-01 | 徐州医科大学 | mPGES-2作为预防和/或治疗衰老疾病的药物靶点的应用 |
CN114129577A (zh) * | 2021-12-15 | 2022-03-04 | 徐州医科大学 | 苯磺酰胺化合物在制备预防和/或治疗衰老疾病的药物中的用途 |
CN114107272B (zh) * | 2021-12-15 | 2022-06-24 | 徐州医科大学 | mPGES-2作为靶点在开发或筛选或制备用于预防和/或治疗衰老疾病的药物中的应用 |
CN114748487A (zh) * | 2022-03-22 | 2022-07-15 | 徐州医科大学 | 苯磺酰胺化合物在制备调节麻醉效应的药物中的用途 |
CN114748487B (zh) * | 2022-03-22 | 2023-09-26 | 徐州医科大学 | 苯磺酰胺化合物在制备调节麻醉效应的药物中的用途 |
CN115590862A (zh) * | 2022-11-08 | 2023-01-13 | 徐州医科大学(Cn) | 苯磺酰胺化合物在制备治疗和/或预防常染色体显性遗传多囊肾病的药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN111419835B (zh) | 2021-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111419835B (zh) | 苯磺酰胺化合物在制备治疗糖尿病的药物中的用途 | |
AU2017200745B2 (en) | Opioid receptor ligands and methods of using and making same | |
US20120135997A1 (en) | Pharmaceutical composition comprising a lactam or benzenesulfonamide compound | |
TW201040141A (en) | Isothiourea derivatives or isourea derivatives having BACE1 inhibitory activity | |
CN113501821B (zh) | 具有mgat-2抑制活性的稠合环衍生物 | |
JP5744886B2 (ja) | シクロペンタンカルボキサミド誘導体、このような化合物を含む薬物及びそれらの使用 | |
KR20130109943A (ko) | 항암 및 항증식 활성을 나타내는 시클로프로필 디카르복사미드 및 유사체 | |
EP2891649B1 (en) | Prolylhydroxylase inhibitors and methods of use | |
CA2890886A1 (en) | Indole carboxamide derivatives as p2x7 receptor antagonists | |
TW202019880A (zh) | 作為神經激肽-1受體拮抗劑的化合物及其用途 | |
TW201100400A (en) | Piperazine compound capable of inhibiting prostaglandin d synthase | |
JPWO2018021447A1 (ja) | ドーパミンd3受容体拮抗作用を有する含窒素縮環化合物 | |
TW201920196A (zh) | 作為vanin抑制劑之雜芳族化合物 | |
TW202023550A (zh) | 作為vanin抑制劑之雜芳族化合物 | |
KR20100135266A (ko) | Npy y5 수용체 길항 작용을 갖는 화합물 | |
WO2015064714A1 (ja) | オートタキシン阻害活性を有する1-置換イミダゾピリミジノン誘導体 | |
WO2012020725A1 (ja) | Npy y5受容体拮抗作用を有するヘテロ環誘導体 | |
TW201643143A (zh) | 抑制氧化壓迫引發的神經細胞死亡之化合物 | |
EP3725780B1 (en) | Sulfonamide derivative or pharmaceutically acceptable acid-addition salt | |
EP4286371A1 (en) | Pyrazolamide derivative, preparation method therefor, and application thereof | |
BRPI0718510A2 (pt) | Derivados de 3-amino piridina para o tratamento de desordens metabólicas | |
EP3891130B1 (en) | Ire1 small molecule inhibitors | |
WO2019146740A1 (ja) | ドーパミンd3受容体拮抗作用を有する環式化合物 | |
JP2014533662A (ja) | Crth2受容体拮抗薬としての窒素含有縮合環式化合物 | |
KR101893237B1 (ko) | Npy y5 수용체 길항 작용을 갖는 5원환 방향족 복소환 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Sun Ying Inventor after: Cai Jie Inventor after: Quan Lingling Inventor after: Zhong Dandan Inventor after: Zhang Rumeng Inventor after: Jia Zhanjun Inventor after: Guo Dong Inventor before: Sun Ying Inventor before: Gao Hang Inventor before: Quan Lingling Inventor before: Zhang Rumeng Inventor before: Wan Zhikang Inventor before: Jia Zhanjun Inventor before: Zhong Dandan |
|
GR01 | Patent grant | ||
GR01 | Patent grant |